Monthly Archives: September 2010

Biosimilars: This Decade's Most Disruptive Technology

Shakespeare said it best: to be or not to be? It’s decision time for Big Pharma on entering the biosimilar space. Biosimilars are the pharmaceutical industry’s story not yet told: the field is touted as bright with promise but regulatory uncertainties and gaps in the competitive turf for individual companies continue to dampen the roots […]
Posted in Biotech, Strategy, Technology | Leave a comment

Social Media and Healthcare Consumers: A Report

In the past decade, social networking has changed the way most of us live our day-to-day lives. So how has it affected pharma’s relationship with consumers, and vice versa? A recent report from ROI Research grants a glimpse into this changing relationship. Social networking is no longer something people (patients, healthcare providers, physicians) are merely […]
Posted in E-Media, social media, Technology | Tagged , , , , | Leave a comment

Big Pharma Reps Still Competing with Local Players in Emerging Markets

Although pharma is an increasingly global marketplace, the relative rankings of companies are becoming more localized — with significant variations — according to a new Cegedim survey of physician attitudes towards reps in the major western markets and Brazil, India, Russia, and China. According to the International Rep Quality survey, physicians tend to favor domestic […]
Posted in Emerging Markets, Europe, Guest Blog, Marketing, Sales | Tagged , , , , , , | Leave a comment

Recasting Big Pharmas R&D Role: Wellcome Trust or Wal-Mart?

New research suggests it’s time industry took a radically different approach to drug development, leaving compound innovation to others while mobilizing its global scale and promotional muscle to drive timely acceptance in the marketplace. The biggest strategic issue confronting Big Pharma today is balancing that legacy of ”big” — maintaining the capacity to invest in […]
Posted in R&D, Strategy | Tagged , , | Leave a comment

What Is Behind the Genzyme Job Cuts?

Troubled biotech Genzyme’s (Cambridge, MA) planned elimination of over 1,000 jobs (10% of its 12,800 workforce, according to the Boston Globe) over the next 15 months is not related to the takeover bid from French giant Sanofi Aventis, the company has said.
Posted in Deals, Global, Strategy | Tagged , , , , , , | Leave a comment
  • Categories

  • Meta